Application of ITGA8 overexpression reagent in the preparation of drugs to alleviate lung cancer resistance

CRISPR/Cas9 screening found that the ITGA8 gene was overexpressed in lung adenocarcinoma. The ITGA8 overexpression reagent was used to improve the sensitivity of lung cancer to avitinib, which solved the problem of lung cancer drug resistance and significantly reduced the proliferation and invasion of lung cancer cells. ability to improve treatment effect.

CN118490847BActive Publication Date: 2024-11-08TIANJIN MEDICAL UNIV GENERAL HOSPITAL AIRPORT HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410978416.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-08
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

The resistance to EGFR-TKIs of lung cancer leads to difficulties in treatment. The existing research mainly focuses on the development of new targeted drugs or inhibiting bypass pathways, and there is a lack of methods to effectively improve the sensitivity of lung cancer to ivetinib.

Method used

Through CRISPR/Cas9 whole genome screening technology, it was found that the ITGA8 gene was overexpressed in lung adenocarcinoma cells. The use of ITGA8 overexpression reagents, including lentiviral vectors, increased the sensitivity of lung cancer cells to Avitinib and reduced proliferation, migration and invasion. ability.

Benefits of technology

It significantly improves the sensitivity of lung cancer cells to Avetinib, reduces the proliferation, migration and invasion ability of lung cancer cells, and improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118490847B_ABST
    Figure CN118490847B_ABST
Patent Text Reader

Abstract

The present application provides the use of an ITGA8 overexpression reagent in the preparation of a drug for alleviating lung cancer resistance, wherein the lung cancer resistance is lung cancer resistance to Avitinib. The present application experiments prove that ITGA8 is a key gene for regulating the sensitivity of lung cancer cells to Avitinib, and upregulating ITGA8 expression can increase the sensitivity of lung cancer cells to Avitinib, reduce the proliferation ability, migration and invasion ability of lung cancer cells, and provide a new approach for the treatment of lung cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of anti-tumor drugs in the field of biomedicine. Specifically, the present application provides the use of ITGA8 overexpression reagents in the preparation of drugs for alleviating lung cancer resistance. Background Art

[0002] Lung cancer is one of the common malignant tumors that threaten human health, and its mortality rate ranks first. In recent years, the emergence of new EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as Avitinib has effectively improved the prognosis of lung cancer patients with EGFR-driven gene mutations. However, the subsequent acquired resistance to EGFR-TKIs has become one of the main problems plaguing clinical treatment.

[0003] At present, the research on acquired resistance to EGFR-TKIs mainly focuses on developing a new generation of targeted drugs based on the molecular mechanism of resistance, or inhibiting or reversing the resistance process by inhibiting the activation of bypass pathways. The CRISPR / Cas9 system is widely used in gene editing technology. sgRNA can guide the Cas9 protein to cut the DNA double strand and achieve gene knockout and knockin during DNA repair. The whole genome screening library technology based on CRISPR / Cas9 can use the lentiviral library expressing sgRNA to cause a large number of protein loss-of-function screening. This study took a different approach and used the CRISPR / Cas9 whole genome library to screen genes that increase the sensitivity of lung adenocarcinoma to EGFR-TKIs to find new treatment directions. Summary of the invention

[0004] On the one hand, the present application provides the use of an ITGA8 overexpression reagent in the preparation of a drug for alleviating lung cancer resistance, wherein the lung cancer resistance is avitinib resistance in lung cancer.

[0005] On the other hand, the present application provides the use of an ITGA8 overexpression reagent and Avitinib in the preparation of a drug for treating lung cancer.

[0006] Furthermore, the lung cancer is lung adenocarcinoma.

[0007] Furthermore, the ITGA8 overexpression reagent is an overexpression plasmid or overexpression vector containing ITGA8.

[0008] Furthermore, the overexpression vector is a lentiviral vector.

[0009] In addition to lentiviral vectors, other overexpression plasmids, lentiviral vectors, and adenoviral vectors can also be routinely selected and designed based on the administration object, overexpression effect requirements, and other aspects.

[0010] Various transcripts and variants other than ITGA8 (Gene ID: 8516) can be routinely verified and used.

[0011] Further, the drug increases the sensitivity of lung cancer cells to Avitinib.

[0012] Furthermore, the drug reduces the proliferation ability of lung cancer cells.

[0013] Furthermore, the drug reduces the migration and invasion capabilities of lung cancer cells.

[0014] Furthermore, the drug is in an injectable or oral dosage form.

[0015] Furthermore, the medicine is in the form of an injection.

[0016] Furthermore, the medicine also contains pharmaceutically acceptable excipients.

[0017] Depending on the dosage form, those skilled in the art can routinely select excipients for the drug of the present application based on knowledge in the pharmaceutical field, including but not limited to fillers, adhesives, lubricants, surfactants, coating agents, capsule shells, taste masking agents, flavor correctants, solvents, co-solvents, suspending agents, pH adjusters, antioxidants, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The results of qRT-PCR and Western blotting detection of ITGA expression levels in different cells.

[0019] Figure 2 These are the results of ITGA expression level detection in H1975_sh—CON, H1975_sh—ITGA8, H1975 / ABIR_OE—CON, and H1975 / ABIR_OE—ITGA8 cell lines.

[0020] Figure 3 These are the results of sensitivity test of H1975_sh—CON, H1975_sh—ITGA8, H1975 / ABIR_OE—CON, and H1975 / ABIR_OE—ITGA8 cell lines to Avitinib.

[0021] Figure 4 These are the results of cell migration and invasion ability detection of H1975_sh—CON, H1975_sh—ITGA8, H1975 / ABIR_OE—CON, and H1975 / ABIR_OE—ITGA8 cells.

[0022] Figure 5 These are the results of cell proliferation ability detection of H1975_sh—CON, H1975_sh—ITGA8, H1975 / ABIR_OE—CON, and H1975 / ABIR_OE—ITGA8 cells.

[0023] Figure 6 The results of immunoprecipitation and co-immunoprecipitation experiments for the specific binding of ITGA8 and FAK.

[0024] Figure 7 These are the experimental results of the changes in the sensitivity of lung adenocarcinoma cells to Avitinib caused by knocking down / overexpressing FAK to restore the downregulation / upregulation of ITGA8.

[0025] Figure 8 These are the experimental results of knocking down / overexpressing FAK to reverse the changes in cell migration and invasion ability caused by downregulation / upregulation of ITGA8.

[0026] Fig. 9 These are the experimental results of knocking down / overexpressing FAK to reverse the changes in cell proliferation ability caused by downregulation / upregulation of ITGA8.

[0027] Fig.10 These are the experimental results of the effects of knockdown / overexpression of ITGA8 on the phosphorylation of FAK, SRC and downstream AKT and MAPK.

[0028] Fig.11 Shown are the effects of ITGA8 knockdown on tumor cell proliferation, tumor volume, and tumor-related genes.

[0029] Fig.12 The effects of overexpression of ITGA8 on tumor cell proliferation, tumor volume, and tumor-related genes are shown. DETAILED DESCRIPTION

[0030] The following examples are provided to facilitate a better understanding of the present invention, but are not limited thereto. These examples are only used for illustrative purposes and in no way limit the scope of protection of the present invention.

[0031] Example 1 Expression level of ITGA8 in avitinib-resistant lung gland cells

[0032] By establishing a CRISPR / Cas9 whole genome screening library, ITGA8 was finally screened as a key gene that increases the sensitivity of H1975 cells to Avitinib. The expression of ITGA8 in lung adenocarcinoma cell lines was significantly lower than that in bronchial epithelial cells, and the expression in resistant cell lines was lower than that in sensitive cell lines. The expression of ITGA8 in lung adenocarcinoma tissue was significantly lower than that in adjacent normal tissues; the expression level of ITGA8 was closely related to the TNM stage of patients and was associated with the prognosis of patients with lung adenocarcinoma

[0033] Cell culture:

[0034] Lung adenocarcinoma cell line H1975 cells and bronchial epithelial cells BEAS-2B cells were obtained from the cell bank of the Chinese Academy of Sciences in Shanghai. H1975 / AR (osimertinib-resistant) cells were established by the in vitro classical drug gradient pressure method, and H1975 / ABIR (avitinib-resistant) cells were established by the in vitro classical drug gradient pressure method. H1975 and H1975 / AR cells were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA) containing 10% fetal bovine serum (Gibco, Carlsbad, CA). The cells were cultured in a humidified incubator at 37°C with 5% CO2.

[0035] qRT-PCR detection of ITGA8 expression level:

[0036] Total RNA was extracted using the Trizol method (Invitgen, 340312). RNA (1 μg) was reverse transcribed into cDNA using the PrimeScript RT kit (TAKARA, DRR047). The volume of qPCR was 10 μl, consisting of 5 μl of SYBR qPCR Master Mix (Vazyme, Q321-02), forward primer, reverse primer, template cDNA, and nuclease-free H2O. The relative mRNA levels of specific genes were normalized (internal reference was β-actin). The primer sequences for ITGA8 and ACTB are as follows:

[0037] SEQ ID NO.1(ITGA8—PrimerF) 5'—AGTTACCTTGAATTGGTTGCTGG—3'

[0038] SEQ ID NO.2(ITGA8—PrimerR) 5'—ATGCCATCTGTTCTCCCGTG—3'

[0039] SEQ ID NO.3(β-actin-PrimerF) 5'- ATAGCACAGCCTGGATAGCAACGTAC-3'

[0040] SEQ ID NO.4(β-actin-PrimerR) 5'-CACCTTCTACAATGAGCTGCGTGTG-3'.

[0041] Western blot:

[0042] The cells were lysed with Western and IP lysis buffer (Beyotime Biotechnology, P0013), PMSF (Sigma, 93482), and phosphatase inhibitors (Beyotime Biotechnology, P1046) to extract total protein. The cell lysate was centrifuged at 12,000×g, 4°C for 30 min, and the supernatant was collected and the protein concentration was determined using a BCA protein assay kit (Thermo Fisher Scientific, 23225). After 10% SDS-PAGE, the protein was transferred to a PVDF membrane (Millipore, Billerica, IPVH00010) using an electrophoretic transfer system (Bio-rad). Blocked with 5% skim milk powder at room temperature for 2 hours, then incubated with primary antibodies (1:1000): GAPDH (ORIGENE, TA802563), ITGA8 (ABclonal, A13056), FAK (Proteintech, 12636-1-AP), p-FAK (Affinity, AF3398), incubated overnight at 4°C, washed with 1×TBST (three times), and then incubated with secondary antibodies (Thermo Fisher Scientific, goat anti-rabbit: 31430 or goat anti-mouse: 31460) at room temperature for 1 hour. Then, after incubation with HRP substrate for 1 minute, the gel was exposed using a G-Box gel imager according to the corresponding exposure time. The relative expression of the target protein was quantified using Image J software.

[0043] Statistical analysis:

[0044] Each experiment was repeated at least three times, and the experimental data were expressed as mean ± SEM, and statistical analysis was performed using SPSS 23.0 (SPSS, Inc., Chicago, IL, USA). p < 0.05 indicated statistically significant differences.

[0045] Experimental results:

[0046] qPCR and Western blot results are shown in Figure 1 The results showed that compared with normal cells, ITGA8 was downregulated in lung adenocarcinoma H1975 cells; compared with lung adenocarcinoma H1975 cells, ITGA8 was downregulated in lung adenocarcinoma third-generation EGFR-TKIs-resistant cells H1975 / AR and H1975 / ABIR cells, and the difference was statistically significant (P<0.01).

[0047] Example 2 Effect of ITGA8 on Avitinib-resistant Lung Adenocarcinoma Cells

[0048] Construction of cells with stable knockdown and overexpression of ITGA8:

[0049] The construction and packaging of the knockdown and overexpression ITGA8 lentiviral vectors were provided by Genechem. ITGA8's Gene ID: 8516. The lentiviral vector was GV493.

[0050] The shRNA sequence is SEQ ID NO. 5:

[0051] ccggccTATCGAGTTCAAATCCAATctcgagATTGGATTTGAACTCGATAggtttttg.

[0052] The construction and packaging of lentiviral vectors for knockdown and overexpression of ITGA8 were provided by Genechem. H1975 or H1975 / ABIR cells were seeded in 6-well plates (1×105 cells per well) and cultured in RPMI-1640 medium (Gibco, Carlsbad, CA) containing 10% FBS. The infection reagent (HiTransG P) and siRNA or plasmid were completely mixed and added to the wells. After incubation at 37°C and 5% CO2 incubator for 16 h, fresh complete medium was replaced. After 72 h, the transfection efficiency was detected, and stable cell lines were obtained after puromycin selection. The expression efficiency of cells knocked down or overexpressed ITGA8 was analyzed by qRT PCR and western blot to establish H1975 cells with sh-CON and sh-ITGA8 01-03; and H1975 / ABIR cells with OE-CON and OE-ITGA8.

[0053] Transwell experiment:

[0054] The chambers for the Transwell invasion assay (Corning, Transwell®, 8.0 μM) need to be coated with Matrigel (Corning, 354248, USA). The chambers are placed in a 24-well plate and incubated at 37°C for 4-5 hours after the Matrigel is applied. Wait for the Matrigel to solidify; the Transwell migration assay does not require Matrigel coating. 4H1975 or H1975 / ABIR cells were inoculated into Transwell chambers, 600 μL of 10% FBS culture medium was added to the lower layer of the chamber, and the cells were incubated in an incubator at 37°C with 5% CO2 for 24 h or 48 h. The cells were fixed with paraformaldehyde for 30 min, washed three times with 1×PBS, and then stained with crystal violet (0.1%) for 20 min. The excess crystal violet dye was washed away with 1×PBS, and the cells on the upper layer of the chamber membrane were gently wiped with a cotton swab. After drying at room temperature, the cells were photographed and the number of cells passing through the chamber was counted.

[0055] CCK-8 detection experiment:

[0056] H1975 or H1975 / ABIR cells were seeded in 96-well plates (1×10 4 cells) and cultured overnight. After treating cells with different concentration gradients of Avitinib, discard the old culture medium in the 96-well plate, add 100 μl of diluted CCK-8 reaction solution to each well, and dilute the CCK-8 reaction reagent (Biyuntian Biotechnology, C0038) with cell culture medium at a ratio of 1:10. Incubate in a 37°C, 5% CO2 incubator for 1 hour. Read the absorbance value at 450nm with a Bio-Rad microplate reader. Calculate the relative cell viability value.

[0057] EdU cell proliferation assay:

[0058] H1975 or H1975 / ABIR cells were seeded in 96-well plates (8 × 10 3 After the cells adhered for 24 h, 50 μM EDU dilution prepared with complete culture medium was added. The culture medium was discarded from each well, and 100 μL EDU dilution was added. The cells were incubated in a cell culture incubator for 2 h. Fluorescence staining was performed using an EDU kit (Raybo Bio, C00003). Photos were taken under a fluorescence microscope. The ratio of EDU-labeled proliferating cells to total cells was counted.

[0059] Plate cloning experiment:

[0060] The cells were seeded in a 6-well plate at a density of 800 cells / well. The corresponding concentration of drugs was added the next day and cultured for 21 days. After the culture was terminated, the cells were fixed with methanol for 10 min and stained with 0.5% crystal violet at room temperature for 20 min. The culture dish was thoroughly washed with distilled water and air-dried at room temperature. The number of cell colonies was counted.

[0061] Immunoprecipitation and co-immunoprecipitation experiments:

[0062] The collected cell pellets were treated with western and IP cell lysis buffers, and the protein supernatant was collected. After taking the input group samples, the remaining supernatant was evenly divided into two EP tubes, and the primary antibody and IgG bound to the target protein were added respectively, and the mixture was rotated overnight at 4 °C. The cleaned Agarose (Biyuntian Biotechnology, P2019-50ml) was added to the protein-antibody mixture after overnight, and the mixture was rotated on a 4 °C rotating shaker for 3 h, and then centrifuged in a 4 °C centrifuge. The supernatant was carefully discarded, and the Agarose precipitate coupled with the antibody was retained. Agarose was washed 5 times with 4 °C pre-cooled PBS and western and IP lysis buffers. After the last wash, the supernatant was carefully discarded, and 20 μL 2×loading buffer was added to the Agarose precipitate. After mixing, the metal bath was 100 °C for 5 min, and then it can be used for western blot experiments.

[0063] Statistical analysis:

[0064] Each experiment was repeated at least three times, and the experimental data were expressed as mean ± SEM, and statistical analysis was performed using SPSS 23.0 (SPSS, Inc., Chicago, IL, USA). p < 0.05 indicated statistically significant differences.

[0065] Experimental results:

[0066] Establish stable expression of H1975_sh-CON, H1975_sh-ITGA8 cell lines (sh-ITGA8 03 with the highest knockdown efficiency was selected for subsequent experiments) and H1975 / ABIR_OE-CON, H1975 / ABIR_OE-ITGA8 cell lines (see Figure 2 Knockdown of ITGA8 reduced the sensitivity of H1975 cells to avitinib, while overexpression of ITGA8 increased the sensitivity of H1975 / ABIR cells to avitinib (see Figure 3 When ITGA8 was knocked down, the migration and invasion abilities of H1975 cells were significantly enhanced; when ITGA8 was overexpressed, the migration and invasion abilities of H1975 / ABIR cells were significantly reduced (see Figure 4). When ITGA8 was knocked down, the proliferation ability of H1975 cells was enhanced; and under the treatment of different drug concentrations of avitinib, the proliferation ability of the knockdown group was stronger, indicating that the downregulation of ITGA8 reduced the sensitivity of H1975 cells to avitinib; conversely, when ITGA8 was overexpressed, the proliferation ability of H1975 / ABIR cells was weakened; under the treatment of avitinib, the proliferation ability of the overexpression group was weakened more significantly, reflecting that the upregulation of ITGA8 increased the sensitivity of H1975 / ABIR cells to avitinib. It can be seen that the expression level of ITGA8 is negatively correlated with the proliferation ability of lung adenocarcinoma cells (see Figure 5 Immunoprecipitation and co-immunoprecipitation experiments verified the specific binding of ITGA8 and FAK (see Figure 6 In the response experiment, knocking down FAK can restore the decreased sensitivity of lung adenocarcinoma cells to Avitinib caused by ITGA8 downregulation; overexpression of FAK can restore the increased sensitivity of tumor cells to Avitinib caused by ITGA8 upregulation (see Figure 7 ). Knockdown of FAK can restore the increased cell migration and invasion ability caused by ITGA8 downregulation; overexpression of FAK can restore the weakened cell migration and invasion ability caused by ITGA8 upregulation (see Figure 8 Knockdown of FAK can restore the increased cell proliferation caused by ITGA8 downregulation; overexpression of FAK can restore the weakened cell proliferation caused by ITGA8 upregulation (see Fig. 9 Western blot analysis showed that knockdown of ITGA8 promoted the phosphorylation of FAK, SRC and downstream AKT and MAPK, whereas overexpression of ITGA8 inhibited the phosphorylation of FAK, SRC and downstream AKT and MAPK (see Fig.10 ).

[0067] Example 3 ITGA8 inhibits drug resistance of H1975 cells in vivo

[0068] In vivo xenograft experiments:

[0069] Four-week-old female nude mice purchased from Beijing Huafukang Biological Company were randomly divided into eight groups, with n = 6 in each group. H1975_sh-CON, H1975_sh-ITGA8 cells (as well as H1975 / ABIR_OE-CON, H1975 / ABIR_OE-ITGA8 cells) were cultured at 2×10 7 The cells were resuspended in a concentration of 10 cells / mL PBS, and the nude mice were anesthetized with isoflurane and inoculated subcutaneously in the right groin. Each nude mouse was inoculated with 100 μL of cell suspension. Tumor volume = long diameter × short diameter 2 ×0.5. When the tumor volume reaches 100mm 3At 10 mg / kg / d, the mice were treated with Avitinib and DMSO control. The effects of Avitinib on the body weight and tumor size of nude mice were monitored every other day. After 21 days of administration, the nude mice were killed and the xenograft tumors were removed. The volume and weight of the tumors were measured, and the transplanted tumors were photographed. All animal experiments were reviewed and approved by the Experimental Animal Welfare Ethics Committee of Tianjin Medical University General Hospital.

[0070] Immunohistochemical staining:

[0071] Xenograft tumors were fixed with 4% paraformaldehyde, paraffin-embedded and sectioned. Tissue sections were dewaxed with xylene and hydrated with graded ethanol. Antigen retrieval was performed with sodium citrate repair solution (Biyuntian Biotechnology, China) under microwave boiling. Peroxidase activity was blocked with endogenous peroxidase blocker. Nonspecific sheep serum blocker was used for blocking. Primary antibodies ITGA8 (ABclonal, A13056) (1:200) and Ki 67 (Abcam, ab16667) (1:500) were incubated overnight at 4 °C. The next day, the sections were washed with PBS three times, 5 min each time, and then incubated with secondary antibodies, streptavidin-peroxidase, DAB color development, hematoxylin staining, and neutral resin sealing.

[0072] Statistical analysis:

[0073] Each experiment was repeated at least three times, and the experimental data were expressed as mean ± SEM, and statistical analysis was performed using SPSS 23.0 (SPSS, Inc., Chicago, IL, USA). p < 0.05 indicated statistically significant differences.

[0074] Experimental results:

[0075] Knockdown of ITGA8 significantly accelerated the proliferation rate of tumors, and the difference in tumor volume and weight was significant; at the same time, knockdown of ITGA8 reduced the sensitivity of tumors to Avitinib and the therapeutic effect became worse; IHC results showed that knockdown of ITGA8 increased the levels of p-FAK, p-SRC, p-AKT, and p-MAPK, and the inhibitory effect of Avitinib on p-AKT and p-MAPK was weakened. Ki-67 verified that downregulation of ITGA8 can enhance the proliferation ability of tumors (see Fig.11 ).

[0076] Overexpression of ITGA8 significantly slowed down the proliferation rate of tumors, and the difference in tumor volume and weight was significant; at the same time, overexpression of ITGA8 increased the sensitivity of tumors to Avitinib, and the therapeutic effect became better; IHC results showed that overexpression of ITGA8 downregulated the levels of p-FAK, p-SRC, p-AKT, and p-MAPK, and Avitinib enhanced the inhibitory effect of p-AKT and p-MAPK. Ki-67 verified that upregulation of ITGA8 can weaken the proliferation ability of tumors (see Fig.12 ).

[0077] Finally, it is noted that the above-described embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some or all of the technical features thereof may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. Use of an ITGA8 overexpression reagent and Avitinib in the preparation of a drug for treating Avitinib-resistant lung adenocarcinoma; the ITGA8 overexpression reagent is an overexpression vector comprising the ITGA8 gene.

2. The use according to claim 1, wherein the ITGA8 overexpression reagent is an overexpression plasmid comprising the ITGA8 gene.

3. The use according to claim 1, wherein the ITGA8 overexpression reagent is a lentiviral vector containing the ITGA8 gene.

4. The use according to claim 1, wherein the drug is in an injection form or an oral dosage form.

5. The use according to claim 4, wherein the drug is in the form of an injection.